RxDoctor Payments Data

Joseph Uberti, MD

Hematology & Oncology · Detroit, MINPI 1609813104

Payments from drug & device makers

What this record shows

This record is dominated by education: $23 of the $23 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, AstraZeneca. That places this record below the midpoint for hematology & oncology clinicians in MI, where the typical reported total is $1,604.

$23in general payments, 2019–2025

Across 1 payment — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$23
$571,123in research payments, 2019–2025

Across 137 payments — averaging $4168.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$137K
  • National Marrow Donor Program$117K
  • Incyte Corporation$105K
  • AbbVie$88K
  • Sanofi US Services Inc.$73K
  • Syndax Pharmaceuticals, Inc.$32K
  • plus $19K from 2 others

What the payments were for

  • Education$23100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$23

How this compares

$23 in reported general payments places this provider in the 5th percentile of 282 hematology & oncology providers in Michigan.

See all hematology & oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$85,221
Medicare patients
180
Services billed
850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide11$200,220
ZarxioFilgrastim-Sndz17$60,346
Tacrolimus14$1,674
Acyclovir23$794
Magnesium Sulfate22$289
Tamsulosin Hcl13$224
Montelukast Sodium15$98
Folic Acid13$57

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →